aTyr Pharma Receives 'Hold' Rating from Analysts

Analysts give mixed reviews on the biotech company's prospects

Feb. 28, 2026 at 6:41am

Got story updates? Submit your updates here. ›

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) have been assigned an average recommendation of "Hold" from the seven brokerages currently covering the company. One analyst has rated the stock as a "Sell", five have given a "Hold" rating, and one has issued a "Buy" recommendation. The average 12-month price target among analysts is $25.67.

Why it matters

aTyr Pharma is a clinical-stage biotech company focused on developing novel protein-based therapies. The mixed analyst ratings and price target suggest uncertainty around the company's future prospects and the potential success of its drug pipeline.

The details

The analysts' ratings come as aTyr Pharma continues to advance its research and development efforts. The company is currently studying its lead product candidate, ATYR1923, for the treatment of pulmonary sarcoidosis and other rare lung diseases. aTyr Pharma has also been exploring the use of its Extracellular Modulation platform to identify additional therapeutic candidates for rare and serious diseases.

  • aTyr Pharma reported its latest financial results on February 28, 2026.

The players

aTyr Pharma, Inc.

A clinical-stage biotechnology company focused on developing novel protein-based therapies that modulate the extracellular matrix and immune pathways.

Vanguard Group Inc.

A major institutional investor that owns a significant stake in aTyr Pharma.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The mixed analyst views on aTyr Pharma highlight the uncertainty surrounding the company's future prospects as it continues to advance its drug pipeline for rare and serious diseases. Investors will be closely watching for updates on the progress of the company's lead candidate, ATYR1923, and any potential breakthroughs in its Extracellular Modulation platform.